New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 23, 2014
07:43 EDTCLVSClovis price target raised to $104 from $94 at Leerink
Leerink raised its price target for Clovis shares to $104 calling the stock a top pick for 2014. The firm sees multiple pipeline catalysts for Clovis and keeps an Outperform rating on the stock.
News For CLVS From The Last 14 Days
Check below for free stories on CLVS the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
April 15, 2014
11:01 EDTCLVSClovis volatility increases on wide price movement
Subscribe for More Information
April 10, 2014
10:24 EDTCLVSClovis volatility elevated
Subscribe for More Information
April 3, 2014
06:33 EDTCLVSFoundation Medicine and Clovis Oncology partner for cancer diagnostic
Foundation Medicine (FMI) and Clovis Oncology (CLVS) are expanding their ongoing collaboration to incorporate a coordinated regulatory strategy for the development of a novel Premarket Approval companion diagnostic test. This test is designed for use by physicians to identify patients most likely to respond to rucaparib, Clovis’ poly polymerase inhibitor currently the subject of Phase 2 and Phase 3 clinical trials in patients with ovarian cancer. This companion diagnostic is being developed in parallel with the clinical development of rucaparib to facilitate an FDA submission of the PMA for the companion diagnostic concurrent with the New Drug Application for rucaparib.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use